Aciclovir topical patch - Labtec

Drug Profile

Aciclovir topical patch - Labtec

Alternative Names: Acyclovir topical patch - Labtec; LabiPatch

Latest Information Update: 20 Apr 2011

Price : $50

At a glance

  • Originator Labtec
  • Developer tesa Labtec
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Phase I Herpesvirus infections

Most Recent Events

  • 20 Apr 2011 Clinical development is ongoing in Germany
  • 22 Jun 2010 GlaxoSmithKline acquires exclusive marketing rights for the aciclovir topical patch from Labtec
  • 11 May 2006 Phase-I clinical trials in Herpesvirus infections in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top